Therapies targeting of MAT2A, RIOK1, or other PRMT5 co‐complex members selectively affect MTAP‐deleted cancers while sparing MTAP‐expressing normal tissues, which address the unmet clinical need of human cancers with the deletion of the MTAP locus [8]. This evidence concerns the gene PRMT5 and cancer.